Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

The idea that a man could receive regular exams and still wind up with a late-stage discovery? It doesn’t surprise me at all.

Astellas & Pfizer’s Xtandi shows long-term overall survival in metastatic hormone-sensitive prostate cancer: Tokyo Saturday, May 24, 2025, 13:00 Hrs [IST] Astellas Pharma Inc. a ...

Former US president Joe Biden’s health was a matter of intense focus while he was in office due to his episodes of ...

Here’s what you should know about PSA screening, why medical guidelines vary and why individualized approaches are essential ...

The aggressiveness of a cancer is based on several factors, including the tumor's grade and stage, and the cells' genetic ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, if any, might work best.

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year ...